Japan neurology devices market to reach USD 870M in 2030

Neurological illnesses such as Alzheimer’s disease and stroke are widespread in Japan, and with the aging demographic, the incidence of these conditions continues to rise. In light of this, the Japan neurology devices market is expected to reach $870 million in 2030, forecasts GlobalData, a leading data and analytics company.

GlobalData’s research reveals that, in terms of value, Japan is the largest market for neurology devices in the Asia-Pacific region, accounting for around 35% in 2023.

Pratibha Thammanabhatla, Medical Devices Analyst at GlobalData, comments: “The currently available diagnostic tests are invasive, complex, and expensive. Acknowledging the increasing prevalence of neurological disorders and addressing the associated diagnostic challenges is imperative. Innovation, alongside new initiatives and robust partnerships, holds the potential to overcome these challenges.”

Against this background, The National Center for Neurology and Psychiatry (NCNP) in Japan and NTT Corporation joined forces in September 2023 to create a Brain Bio-Digital Twin technology that would help identify and prevent mental health disorders and eliminate the need for expensive invasive testing.

The goal is to construct a digital twin processing platform by the end of 2024 to gather several forms of data from NCNP-provided medical examinations. The NCNP is currently gathering data from PET scans and bio samples to build a comprehensive collection for analyzing cranial nerve disorders. This data library aims to facilitate the development of precise maps and biological models for enhanced understanding and research in this field.

Thammanabhatla concludes: “Although digital twin technology is currently being explored in Japan for behavioral disorders and cardiac care; a broader application of these techniques is expected to emerge over time as NTT and NCNP aim to create a system that not only detects and prevents disease, but also foresees an individual’s risk of severe adverse drug reactions even before taking medicines. Further research is needed to examine whether the application of this technology can also be expanded to make better use of resources and planning infrastructure when faced with an emergency such Covid-19.” GlobalData